Oncimmune expects material revenues and profits from enlarged lung cancer study

Commercial terms are being negotiated for the study, which is expected to commence later this year and will last approximately 24 months.

ECLS study will test 200,000 people

Diagnostics group Oncimmune Holdings PLC (LON:ONC) says its cash position is materially ahead of expectations as it moves towards a major study for its EarlyCDT lung cancer test.

In June, Oncimmune released the results of a study of the diagnostic tool on 12,210 people in Scotland.

The EarlyCDT-Lung test was used alongside x-rays and CT scans to check for the killer disease and hit its primary end point of reducing the incidence of late-stage lung cancer.

Oncimmune said the study showed the commercial potential of EarlyCDT, which will now be tested further in a 200,000 person study.

Commercial terms are being negotiated for the study, which is expected to commence later this year and will last approximately 24 months.

The study is expected to add materially to revenues and profits over its duration, said the AIM-listed company.

Outside of the UK, Oncimmune has already negotiated a number of distribution agreements for EarlyCDT, which amount to guaranteed revenues of at least £34.6mln.

Some of these have taken longer than expected to conclude so sales this year will undershoot expectations, but lower operating costs will mean reduced losses and the better cash position than expected.

Elsewhere, a study of EarlyCDT in 1,000 people in China will generate top-line results in the final quarter of 2019 after which Chinese approval for the diagnostic tool will be sought.

Oncimmune added it is also in discussions with a number of possible partners for its autoantibody panels.

Quick facts: Oncimmune

Price: 50.5 GBX

Market: AIM
Market Cap: £31.94 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...



New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

2 weeks, 4 days ago

2 min read